(Q38071385)

28 August 2017

1 reference

title

How to optimize HCV therapy in genotype 1 patients: management of side-effects (English)

1 reference

28 August 2017

Angeli Chopra

1

1 reference

28 August 2017

Patricia L Klein

series ordinal

2

1 reference

28 August 2017

Thia Drinnan

series ordinal

3

1 reference

28 August 2017

Samuel S Lee

series ordinal

4

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

33 Suppl 1

1 reference

28 August 2017

page(s)

30-34

1 reference

The global burden of hepatitis C

28 August 2017

cites work

1 reference

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

The metabolism of ribavirin in erythrocytes and nucleated cells

21 January 2018

1 reference

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12080

1 reference

28 August 2017

1 reference